High incidence of secondary hypertension in patients referred for renal denervation-the Copenhagen experience

Blood Pressure

Volumn 23, Issue 4, 2014, Pages 233-239

  Olsen, Lene Kjær ^a   Kamper, Anne Lise ^a   Svendsen, Jesper Hastrup ^a,b,c   Bang, Lia Evi ^a   Frimodt Moller, Marie ^a   Kelbæk, Henning ^a   Sander, Mikael ^a   Feldt Rasmussen, Bo ^a,b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

Author keywords

Eligibility; Hypertension; Renal denervation; Secondary hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESISTANT HYPERTENSION; TRANSTHORACIC ECHOCARDIOGRAPHY; DENMARK; INNERVATION; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; SYMPATHECTOMY;

BLOOD PRESSURE MONITORING, AMBULATORY; DENMARK; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYMPATHECTOMY;

EID: 84904661279     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2013.867655     Document Type: Article

References (18)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005; 365: 217-223. Epub 2005/01/18.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. Epub 2002/12/21.
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010; 121: e46-e215. Epub 2009/12/19.
4. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004; 43: 10-17. Epub 2003/11/26.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403-1419. Epub 2008/04/09.
6. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642. Epub 2012/03/02.
7. Anderson GH, Jr., Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994; 12: 609-615. Epub 1994/05/01.
8. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res: Off J Japan Soc Hypertens. 2004; 27: 193-202. Epub 2004/04/15.
9. Ott C, Schneider MP, Schmieder RE. Ruling out secondary causes of hypertension. EuroIntervention. 2013; 9 Suppl R: R21-R28. Epub 2013/06/14.
10. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281. Epub 2009/04/01.
11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplic-ity HTN-2 Trial): A randomised controlled trial. Lancet. 2010; 376: 1903-1909. Epub 2010/11/26.
12. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013; 128: 132-140. Epub 2013/06/20.
13. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57: 911-917. Epub 2011/03/16.
14. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International Expert Consensus Statement: Percutaneous transluminal renal den-ervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013. Epub 2013/09/12.
15. Schmieder RE RJ, Grassi G, Kjeldsen SE, Mancia G, Narkie-wicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013; 9: 58-66.
16. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: Renal denervation-an interventional therapy of resistant hypertension. J Hypertens. 2012; 30: 837-841. Epub 2012/04/04.
17. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: When enthusiasm meets reality in real-life patients. J Am Coll Cardiol. 2012; 60: 2422-2424. Epub 2012/11/13.
18. Mahfoud F, Vonend O, Bruck H, Clasen W, Eckert S, Frye B, et al. [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]. Dtsch Med Wochenschr. 2011;136:2418. Epub 2011/11/04. Interventionelle renale Sympathikusdenervation zur Behand-lung der therapieresistenten Hypertonie.